| Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|
 Filter
|
Third-party reanalysis
|
SRA Run Selector
|
Feb 01, 2016
|
|||||
| GSE64832 |
UTX inhibition as selective epigenetic therapy against TAL1-driven T cell acute lymphoblastic leukemia
|
|
2 | Ottawa Hospital Research Institute | Feb 01, 2016 |
